Table 3:

Intraindividual comparisons of model-free and pharmacokinetic parameters between stable and progression posttreatment glioma groups^{^a}

DCE Parameters	Treatment-Related Change Group			Progression Group			P Value*^{^b}	P Value+^{^b}
DCE Parameters	Gadobutrol	Gadoterate Meglumine	P Value	Gadobutrol	Gadoterate Meglumine	P Value	P Value*^{^b}	P Value+^{^b}
Model-free method
IAUC30	3.43 ± 1.59	3.90 ± 1.84	.399	4.69 ± 3.24	4.88 ± 2.25	.870	.15	.34
IAUC100	15.82 ± 7.88	17.91 ± 9.21	.446	20.55 ± 13.69	21.20 ± 9.51	.895	.22	.34
IAUC200	15.80 ± 7.87	17.89 ± 9.20	.446	20.54 ± 13.67	21.18 ± 9.49	.896	.22	.34
IAUC300	15.82 ± 7.88	17.91 ± 9.20	.445	20.56 ± 13.67	21.21 ± 9.50	.894	.22	.34
IAUC400	15.79 ± 7.87	17.88 ± 9.18	.445	20.54 ± 13.66	21.17 ± 9.49	.897	.22	.34
IAUC500	15.81 ± 7.87	17.90 ± 9.19	.445	20.55 ± 13.66	21.18 ± 9.50	.898	.22	.34
IAUC600	15.82 ± 7.87	17.91 ± 9.20	.445	20.57 ± 13.66	21.20 ± 9.50	.897	.22	.34
IAUC700	15.83 ± 7.87	17.92 ± 9.20	.445	20.57 ± 13.67	21.21 ± 9.51	.896	.22	.34
IAUC800	15.83 ± 7.87	17.92 ± 9.20	.445	20.58 ± 13.67	21.21 ± 9.51	.896	.22	.34
IAUC900	16.64 ± 8.11	18.29 ± 9.45	.651	19.78 ± 13.43	20.69 ± 8.71	.859	.51	.54
IAUC1000	16.65 ± 8.11	18.30 ± 9.46	.651	19.79 ± 13.43	20.70 ± 8.72	.858	.51	.54
IAUC1100	16.66 ± 8.11	18.31 ± 9.46	.651	19.79 ± 13.44	20.72 ± 8.73	.857	.51	.54
Pharmacokinetic method
K^trans (min^–1)	0.015 ± 0.007	0.016 ± 0.008	.531	0.017 ± 0.011	0.018 ± 0.007	.921	.45	.66
K_ep (min^–1)	0.130 ± 0.041	0.132 ± 0.041	.878	0.121 ± 0.044	0.133 ± 0.044	.528	.58	.95
V_e (%)	16.374 ± 9.615	16.220 ± 6.271	.952	20.169 ± 10.750	19.023 ± 9.085	.780	.31	.31
V_p	1.045 ± 0.508	1.177 ± 0.591	.454	1.374 ± 0.916	1.408 ± 0.611	.915	.20	.29
Wash-in rate	0.813 ± 0.521	0.220 ± 0.590	.002	0.845 ± 0.859	0.404 ± 0.738	.191	.86	.44
Washout rate	0.0009 ± 0.0004	0.0015 ± 0.0016	.107	0.0013 ± 0.0012	0.0031 ± 0.0033	.091	.17	.08

↵a Data are means. P values are from paired t-tests.
↵b P* values and P+ values are from Student t tests between the treatment-related-change and tumor-progression groups for gadobutrol and gadoterate meglumine, respectively.